Inventiva S.A.

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.

Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.

Daix (France), Long Island City (New York, United States) , June 2 4 , 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that the abstract “Lanifibranor Improves Markers of Cardiometabolic Health in Patients with NASH and Type 2 Diabetes, Correlated With Responses in Adiponectin Levels” has been selected for poster presentation during the American Diabetes Association's 83r d Scientific Sessions taking place on June 23-26, 202 in San Diego, United States.

Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association

Inventiva (NASDAQ: IVA ) stock is rising higher on Wednesday following the release of positive results from a Phase II clinical trial. This clinical trial has Inventiva evaluating the efficacy and safety of lanifibranor as a treatment for patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2D).

Why Is Inventiva (IVA) Stock Up 38% Today

Daix (France), Long Island City (New York, United States), June 13, 2022 –Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced positive topline results of the clinical study conducted by Dr. Kenneth Cusi from the University of Florida, evaluating lanifibranor in patients with NAFLD and type 2 diabetes mellitus (T2D).

Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD

Daix (France), Long Island City (New York, United States) / Paris (France) and Waltham (United States), June 8, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs and Echosens, a high-technology company providing a comprehensive range of diagnostic solutions for liver health, today announce their collaboration in raising awareness about NASH and increase access to screening for patients at risk of developing NASH.

Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients

Daix (France), Long Island City (New York, United States), June 7, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that five abstracts have been selected for poster presentation at the upcoming International Liver Congress™ 2023 hosted by the European Association for the Study of the Liver (EASL) on June 21-24, 2023 in Vienna, Austria.

Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023

Daix (France), Long Island City (New York, United States), May 26, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with unmet medical need, today announced the results of the votes of its Combined Shareholders' Meeting.  The Combined Shareholders' Meeting was held on Thursday May 25, 2023 at 2 p.m.

Results of the votes of the Combined Shareholders' General Meeting of May 25, 2023

Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a Sino Biopharm's subsidiary, receives IND approval from the NMPA to initiate the clinical development in mainland China of lanifibranor in NASH Sino Biopharm will participate in the ongoing NATiV3 Phase III trial which, if positive, is expected to support a potential NDA filing in China In parallel, Sino Biopharm will conduct a Phase I clinical pharmacology study Following this regulatory decision, Inventiva is eligible to the first of the 2 short term milestones amounting to a total of $5 million, under the license and collaboration agreement with CTTQ   Daix (France), Long Island City (New York, United States), Beijing/Hong Kong (China), May 25, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, and Sino Biopharm, through its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China

Daix (France), Long Island City (New York, United States), May 16, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today reported financial information for the first quarter of 2023, including its cash, cash equivalents and revenues, and provided a corporate update.

Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update

Daix (France), Long Island City (New York, United States), May 4, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of May 25, 2023.

Combined General Meeting of May 25, 2023. Availability of the preparatory documents

Inventiva S.A. (NASDAQ:IVA ) 2022 Full Year Results Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Frédéric Cren – Chief Executive Officer Jean Volatier – Chief Financial Officer Michael Cooreman – Chief Medical Officer Conference Call Participants Seamus Fernandez – Guggenheim Securities Annabel Samimy – Stifel Ed Arce – H.C.

Inventiva S.A. (IVA) 2022 Full Year Results Earnings Call Transcript

Daix (France), Long Island City (New York, United States) , March 30, 2023 Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that it had filed its 2022 Universal Registration Document for the year ended December 31, 2022, including the management report and the annual financial report, with the French “Autorité des Marchés Financiers” (AMF) and its 2022 Annual Report on Form 20-F for the year ended December 31, 2022 with the U.S. Securities and Exchange Commission (SEC).

Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F

Cash and cash equivalents at €86.7 million and short term deposits at €1 million as of December 31, 2022 compared to €86.6 million and €8.8 million, respectively as of December 31, 2021

Inventiva reports its 2022 full-year results

Daix (France), Long Island City (New York, United States) , March 23 , 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2022 full-year financial results on Thursday, March 30, 2023.

Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results

Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today reported certain preliminary financial results as of and for the year ended December 31, 2022.

Correction: Inventiva reports preliminary financial results for Full-Year 2022¹

Inventiva reports preliminary financial results for Full-Year 2022¹

Daix (France), Long Island City (New York, United States), January 26, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with unmet medical need,  today announced the results of the votes of its Combined Shareholders' General Meeting.

Results of the votes of the Combined Shareholders' General Meeting of January 25, 2023

Proposed changes are expected to be beneficial to the lanifibranor clinical program by reducing the number of biopsies and the trial duration, eventually offering all patients in the trial access to treatment and potentially expanding the addressable patient population to patients with NASH and compensated cirrhosis

Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis

Daix (France), Long Island City (New York, United States), January 3, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of January 25, 2023.

Combined General Meeting of January 25, 2023 - Availability of the preparatory documents

Daix (France) , Long Island City (New York, United States ), December 12 , 2 022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today announced the receipt of the €25 million payment under the first tranche of the unsecured loan agreement executed with the European Investment Bank (“EIB”) on May 16, 2022 with a maturity date of December 2026 (the "Finance Contract").

Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank

Daix (France), Long Island City (New York, United States ), November 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today announced that the United States Patent and Trademark Office (“USPTO”) granted a patent (U.S. Patent No. 11,504,380) that protects the use of lanifibranor for the treatment of cirrhotic patients at risk of progressing from compensated stage to decompensated stage. This patent will expire on November 8, 2039.

Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US

Daix (France), Long Island City (New York, United States), November 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of nonalcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announces that, effective on November 9th, 2022, Inventiva's board of directors coopted Dr. Lucy Lu as the Director of its Board of Directors in lieu of Sofinnova Partners.

Inventiva announces a new Director of the Board of Directors

Daix (France), Long Island City (New York, United States), November 10, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today reported its cash position as of September 30, 2022 and its revenues for the first nine months of 2022.

Inventiva reports 2022 Third Quarter Financial Information¹

Daix (France), Long Island City (New York, United States), October 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of nonalcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that a scientific abstract has been selected for poster presentation at the upcoming The Liver Meeting® 2022 hosted by the American Association for the Study of Liver Diseases on November 4-8, 2022 in Washington, DC.

Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022

Inventiva S.A. (NASDAQ:IVA ) Q2 2022 Earnings Conference Call September 22, 2022 8:00 AM ET Company Participants Frédéric Cren - Co-Founder and CEO Pierre Broqua - Co-Founder and CSO Michael Cooreman - Chief Medical Officer Jean Volatier - Chief Financial Officer Philip Duong - Head, Investment Conference Call Participants Ed Arce - H.C.

Inventiva S.A. (IVA) Q2 2022 Earnings Call Transcript

Daix (France), Long Island City (New York, United States), September 22, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today reported its interim financial results for the six months ended June 30, 2022, and provided a corporate update.

News for Inventiva S.A. Stock (IVA)